Here, we demonstrate a more comprehensive mechanistic approach to exploiting MDM2/MDMX pro-oncogenic activity through targeting MDM2 homodimer and heterodimer disruption, where anti-cancer activity observed with DRx-098D-R indicates MDM2 dimerization as a potential therapeutic vulnerability in both TP53 WT and MT cancer. This evidence concerns the gene TP53 and cancer.